According to board-certified dermatologist Kim Nichols, MD, founder of NicholsMD (Greenwich, Conn.), with the medical aesthetic market continually accelerating and the demand for non-invasive aesthetic procedures continuing to rise, it is important to stay up to date with new research and studies on new and treatments and technology.
What’s Notable – According to the Experts
In November 2022 AviClear by Cutera (Brisbane, Calif.) announced that their laser device has been FDA cleared, and Health Canada approved to treat mild, moderate and severe acne. “We recently introduced AviClear to our practice,” Dr. Nichols reported. “The device is safe on all skin types (Fitzpatrick I-VI) and targets and suppresses the sebaceous glands. With this kind of technology, we are slowly phasing out the need for prescription medications.”
When it comes to injectable treatments and products, Dr. Nichols highlighted JUVÉDERM VOLUX™ XC from Allergan Aesthetics. “This highly cohesive, hyaluronic acid-based gel filler is the first and only FDA-approved filler for jawline definition,” she noted. “In addition, a new category of ‘skin boosters’ are in the pipeline for approval, which are gentle dermal fillers designed to be injected into the most superficial layer of the dermis for hydration and prolonged stimulation of collagen production. Introducing products like this to the market showcases how innovative the aesthetic world continues to be.”
Alexander Rivkin, MD, cosmetic surgeon and founder of RIVKIN Aesthetics (Beverly Hills, Calif.), is globally recognized for providing state-of-the-art nonsurgical aesthetic treatments and sees an expanded future in another biostimulating product – Renuva® (MTF Biologics). “Renuva looks interesting. It is an injectable adipose matrix that stimulates your own adipose cells and is somewhat comparable to fat grafting without having to harvest. Currently, it is an off the shelf fat grafting injectable,” he clarified.
At the same time, Dr. Rivkin explained that he was not surprised with the removal of Qwo (Endo International) from the market. “I am glad to see the removal of faulty technology while anticipating the implementation of better quality technology.”
Benjamin Caughlin, MD, a double board-certified facial plastic surgeon in Chicago, Ill., finds that many of the current fillers can achieve similar outcomes, but he is excited about the long-lasting effects of the daxibotulinumtoxinA-Ianm injectable, DAXXIFY, that will be available in 2023. “This is a long-lasting neurotoxin and probably the hottest one that has been FDA approved – the approval is significant in that it lasts six months, and it has been shown to last up to nine months in some cases.
Dr. Caughlin also validated the resurgence of threads taking place. “I do think there is some filler exhaustion among patients, so they are looking at other options, like thread lifts. One of the biggest benefits of today’s threads is the rigid structure the lift provides, while the volume component and collagen stimulation are also added benefits.”
Doris Day, MD, a board-certified dermatologist in New York City, N.Y., who specializes in aesthetic dermatology, finds limited use for thread lifting in her practice. “I use smooth and twisted threads for acne scars and find they work very well for that. I also use threads for skin tightening/smoothing of the stomach; it is a niche therapy but I can achieve excellent results with careful patient selection and treatment,” she reported.
This is a sample article from The Aesthetic Guide.
Become a free member of the AMS to access all digital issues.
Continue reading here: The Aesthetic Guide#CosmeceuticalsandTopicalTherapies#Injectables#Innovation-Aesthetics3.0#LasersandEBDs#SuspensionThreads